↓ Skip to main content

Interferon Beta for Primary Progressive Multiple Sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, January 2010
Altmetric Badge

Mentioned by

wikipedia
2 Wikipedia pages

Citations

dimensions_citation
50 Dimensions

Readers on

mendeley
137 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Interferon Beta for Primary Progressive Multiple Sclerosis
Published in
Cochrane database of systematic reviews, January 2010
DOI 10.1002/14651858.cd006643.pub3
Pubmed ID
Authors

Juan Ignacio Rojas, Marina Romano, Agustín Ciapponi, Liliana Patrucco, Edgardo Cristiano

Abstract

This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006643. DOI: 10.1002/14651858.CD006643.pub2).Therapeutic trials with ss-interferon in Multiple Sclerosis (MS) have mainly focused on remitting-relapsing multiple sclerosis (RRMS), demonstrating a reduction in relapse rate. However, there is not enough evidence about their efficacy in patients with primary progressive multiple sclerosis (PPMS).

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 137 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
Italy 1 <1%
United Kingdom 1 <1%
Canada 1 <1%
Spain 1 <1%
Unknown 132 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 21 15%
Student > Master 20 15%
Student > Bachelor 16 12%
Student > Ph. D. Student 15 11%
Student > Doctoral Student 8 6%
Other 24 18%
Unknown 33 24%
Readers by discipline Count As %
Medicine and Dentistry 49 36%
Nursing and Health Professions 9 7%
Agricultural and Biological Sciences 9 7%
Neuroscience 7 5%
Psychology 5 4%
Other 15 11%
Unknown 43 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2018.
All research outputs
#8,616,072
of 25,576,801 outputs
Outputs from Cochrane database of systematic reviews
#9,758
of 13,155 outputs
Outputs of similar age
#51,388
of 173,224 outputs
Outputs of similar age from Cochrane database of systematic reviews
#77
of 118 outputs
Altmetric has tracked 25,576,801 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 13,155 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,224 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 118 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.